RACE ONCOLOGY

AGM Presentation | Managing Director

Peter Molloy

November 2019

Corporate snapshot

SHARES ON ISSUE	
Shares issued	109 m
Options issued (excl. 4m expired 22 Nov 2019)	38 m
Shareholders (at 15/11/19)	903
MARKET CAPITALISATION	
Share price (30-day VWAP to 15 Nov '19)	$0.127
Market value	$14.7 m
Cash (15 Nov '19)	$1.7 m
Enterprise value (EV)	$13.1 m
SIGNIFICANT SHAREHOLDERS	
Bill Garner (Chair)	16.2%
Daniel Tillett (Director & CSO)	8.3%
Total shares held by directors	31.8%



About
Bisantrene

Bisantrene is a cancer chemotherapy drug developed in the 1980s b
Lederle Pharmaceuticals

Bisantrene was tested in more than 40 human trials and showed act
in AML (acute myeloid leukaemia), as well as breast and ovarian car

Bisantrene was approved for AML in France in 1988, but never
commercialised and it disappeared after AHP/Wyeth acquired Led
in 1994

Race was founded in 2016 with the mission to rescue Bisantrene an
bring this valuable drug back into clinical practice

Since then, Race has:

- Successfully manufactured Bisantrene
- Built a strong patent position (3 granted)
- Owns US Orphan Drug designation (7 years exclusivity)
- Secured Rare Paediatric Disease (RPD) designation with the potential to receive a Priority Review Voucher (PRV)

Race's original plan for Bisantrene

1. **Adult AML** – Obtain FDA approval for Bisantrene under the 505(b)(2) pathway as a single agent for treatment of adult relapsed/refractory (R/R) AML

   Filed IND to support US registration trial, based on historical Phase II single agent studies; sought a licensing partner to fund the trial

2. Develop Bisantrene for paediatric AML under the RPD designation and win a PRV valued at around US$100m

3. In parallel, generate usage and revenues through a Named Patient Program (NPP) outside US (Europe)

However, the AML landscape has recently changed, which affects the adult AML registration plan and the viability of NPP

But these changes also point to exciting & valuable new clinical opportunities for Bisantrene

How the AML landscape has changed

Up to 2017, there had been no advances in AML treatment for at least 30 years. However, since 2017:

- 8 new drugs approved for AML
- 538 AML clinical trials underway
- 216 different drugs being trialled
- Many trials, few patients – competition for trial patients is intense, especially in R/R disease

R/R AML now focused on combination drug therapy, not single agent

- A single-agent registration trial would be impossible to recruit given competition for patients
- Also unattractive to licensing partners, because of the length and cost of the trial, and limited market for a single agent therapy in adult R/R AML

NPP opportunities are very limited, due to the abundance of clinical trials

- Clinical trials are a 'free' treatment for the patient and doctor
- NPP involves a bureaucratic approval process and payment for the drug

Current AML Treatment

Generalised overview – specific interventions vary greatly



Treatment now dominated by combination therapies

The new strategy for Bisantrene

In October, Race held a company-wide strategy meeting in Houston (Texas) with consultants and advisors to develop a new strategy for Bisantrene, called the '5 Path' strategy



Two pillars of new strategy

New preclinical data was presented showing synergy between Bisantrene and other agents in AML; similar synergies expected in other cancers

Bisantrene has a valuable opportunity in combination therapy in AML and other cancers

There is an exciting opportunity for Bisantrene to be used earlier in the AML treatment cycle, in a unique positioning for treating 'MRD' status

Measurable Residual Disease (MRD) is a major problem in AML and Bisantrene is the potential solution – potentially a 'real breakthrough'

Chief Scientific Officer
Daniel Tillett

November 2019



Why Bisantrene?



Why Bisantrene?

- Bisantrene cured two French girls with AML in the 1980 & 90s
- Both girls are alive today and have their own families





Recent clinical studies have demonstrated the importance of eliminating measurable residual disease (MRD) in AML patients

Why is MRD so important for curing AML patients and what can be done?

The MRD opportunity

The MRD opportunity

Up to 80% of AML patients who are fit enough for induction chemotherapy (3+7) with go into remission (CR) and may then be candidates for a human stem cell transplant (HSCT)

Whether the transplant is successful depends largely on the patient's MRD (Measurable Residual Disease) status at the time of transplant

- MRD(+) patients (those with MRD) have less than 25% two-year survival time
- MRD(-) patients have a 80% survival post transplant = potential cure!

As yet, there are no approved treatments that can change MRD status from (+) to (-) for AML

- Bisantrene is potentially the answer



The MRD opportunity for Bisantrene

Proposed trial

- Patients that are still MRD(+) after induction chemotherapy receive Bisantrene treatment before receiving transplant
- Goal is to convert patients from MRD(+) to MRD(-) status and improve survival

US Key Opinion Leaders (KOL) have indicated that this would represent a 'breakthrough' in the treatment of AML

- Trial could lead to important publications, high visibility in the AML market and potentially early FDA approval for Bisantrene

The MRD positioning would put Bisantrene near the top of the AML treatment pathway

- Much larger market opportunity than R/R AML
- Easier to treat patient population
- Much more attractive for licensing partners

Bisantrene in AML treatment for MRD

Bisantrene could transform cure rates by changing MRD status



The combination opportunity

Previous research (Lederle/NCI) showed that Bisantrene has differential activity over other chemotherapy agents

How does it stack up today using modern research techniques?



The combination opportunity

New preclinical data from ongoing research sponsored by Race shows

- Bisantrene has excellent activity in drug resistant AML cell lines with cancer mutations associated with poor patient prognosis
- Bisantrene has synergy with cytarabine (backbone of AML treatment), as well as nucleoside analogues and targeted drugs

Exciting potential for a series of proof-of- concept (POC) combination trials

- Adult R/R AML
- Paediatric R/R AML
- Breast cancer
- Ovarian cancer and/or other cancers

Bisantrene combinations in AML Treatment

Bisantrene could transform R/R AML treatment



Bisantrene's new 5 Path strategy

1. Phase II MRD trial to advance Bisantrene towards FDA approval under the 505(b)(2) pathway in adult AML patients who are in CR but still MRD(+) (USA)
2. Phase I/II combination trial for adult R/R AML (Australia)
3. Phase I/II combination trial for paediatric R/R AML (Australia/USA)
4. Phase I/II combination trial for breast cancer (Australia)
5. Phase I/II combination trial for ovarian or other cancers (Australia)

1 Phase II MRD trial

Phase II study of Bisantrene treatment after (7+3) induction chemotherapy to change MRD status

Aim to run trial in USA in partnership with a leading US cancer center

Eligibility

MRD(+) patients in CR after induction chemotherapy

Study Design

Open label 7-day Bisantrene 250mg/m²/day treatment

Endpoints

MRD status post-Bisantrene

treatment Post-transplant survival

Goal

Early FDA approval of Bisantrene for MRD(+) patients



2 Bisantrene adult R/R AML trial

Phase I/II Bisantrene combination AML study
Bisantrene plus other approved AML treatments

Aim to run trial in Australia
Lower cost
Does not require IND
R&D Tax credits (43.5% cash rebate)

Eligibility
All AML patients after first relapse

Endpoints
Pharmacokinetics, dosage and safety of the drug combination
CR and progression free survival

Goal
Attract partner for Phase 3 trial

3 Bisantrene paediatric AML trial

Phase I/II paediatric AML Bisantrene combination study
Bisantrene plus other approved AML treatments

Aim is to run trial in US and Australia under IND
Small trial – expected 25-40 patients

Eligibility
Childhood AML patients who meet 'rare paediatric disease' criteria under Race's RPD/PRV designation

Endpoints
Pharmacokinetics, dosage and safety of the drug combination in children
CR and progression free survival

Goal
Gain approval for Bisantrene in US for Rare Pediatric Disease and secure PRV PRVs can be sold on secondary market (range US$75-$150 million)

Doxorubicin Market: Revenue Share (%), By Application, Global, 2018



Bladder Cancer | Kaposi Sarcoma | Leukemia | Lymphoma | Breast Cancer | Others

Source: Mordor Intelligence

Bisantrene
other cancers

Major Players

1. Zydus Cadila
2. Johnson and Johnson
3. Cipla
4. Pfizer Inc.
5. Sun Pharmaceutical Industries Ltd.



4

Breast cancer combination trial

Phase I/II proof-of-concept (POC) trial in breast cancer
Will use drug combinations which preclinical data show synerg
Bisantrene (studies ongoing)

Uses optimal dosing and administration of Bisantrene
Historical breast cancer trials used sub-optimal dosing and admi
of Bisantrene (but still showed good activity!)

Aim to run trial in Australia
Lower cost
Does not require IND approval from FDA
R&D Tax credits (43.5% cash rebate)

Goal
Opens up much larger cancer market than AML (2 million cases e
year)
POC trial to attract pharmaceutical partner for approval trials

5 Ovarian or other cancer trial

Phase I/II proof of concept (POC) trial in ovarian or other cancer
Preclinical trials to be performed to identify those cancers that respond most to Bisantrene and which drug combinations show synergy

Uses optimal dosing and administration of Bisantrene
Historical non-AML cancer trials all used sub-optimal dosing and did not use combinations, but still showed activity for Bisantrene

Aim to run trial in Australia
Lower cost
Does not require IND approval from FDA
R&D Tax credits (43.5% cash rebate)

Goal
Opens up much larger cancer market than AML (2 million cases each year) POC trial to attract pharmaceutical partner for approval trials



Case study
ivosidenib

Approved by the FDA in May 2019 for newly diagnosed AML with a susceptible IDH1 mutation [1]

Early approval from a Phase I/II open label trial of 28 patients
43% CR/CRi [2]

Small Market

700 – 1100 patients in the USA per year

Total Sales

US$300 million per year [3]



1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation
2. https://clinicaltrials.gov/ct2/show/NCT02074839
3. https://www.fiercebiotech.com/special-report/20-tibsovo

Case study
gilteritinib

Approved by the FDA in November 2018 for relapsed or refractory AML with a FLT3 mutation [1]

Approval of gilteritinib based on an interim analysis of the ADMIRAL trial [2]

138 adult patients having a FLT3 ITD, D835, or I836 mutation

CR/CRi ~21%

Small Market

10% of all AML patients

~1000 patients in USA per year

Total Sales

Cost US$400,000 per year per patient [3]



1. https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation
2. https://clinicaltrials.gov/ct2/show/NCT02421939
3. https://www.drugs.com/price-guide/xospata

Benefits of the 5 Path plan

RAC value driver

- Expands the market for Bisantrene by up to 20x
- Early approval potential
- Reduced binary risk
- Increased news-flow

Partnering value

- Larger market expands pool of potential partners
- Bisantrene is more attractive to potential partners

Clinical focus Australia

- Faster (early-stage) clinical outcomes without IND barriers
- Lower cost, especially at current x-rate
- R&D tax credits virtually halve trial costs again

Expanded market potential for Bisantrene

AML remains key market for Bisantrene

- Around 50,000 new cases p.a. and growing due to aging
- Now Bisantrene will target 3 AML segments

AML Segment	Annual Cases (US+EU)
Post-induction CR with MRD+	10,000-12,000
Adult R/R AML (combination)	15,000-20,000
Paediatric AML (combination)	1,800

Bisantrene also targeted at much larger markets

- Combination potential in breast cancer, ovarian cancer and other significant cancer markets



Partnering is our long term goal

US remains our key target market

- **US has <5% of world population but 47% of global pharmaceutical sales**, due to higher pricing (and consumption)
- Partnering deal values are driven by potential in US market

Bisantrene is well-placed in US

- Three granted US patents covering use in a range of cancers and in combination; our patent portfolio is strong
- Orphan drug designation in AML == 7 years' exclusivity after approval
- Rare Pediatric Disease designation == valuable PRV
- Excellent KOL relationships, including Prof. Borje Andersson at MD Anderson Cancer Center in Houston Texas
- Bisantrene manufacturing based in San Diego CA

2018 Global Pharma Sales US$



5 Path plan

Valuable, affordable, fundable

- Bisantrene's role in cancer has been enhanced and expanded
- Potential for early licensing deal and even early approval after in MRD or one of the proof-of-concept combination trials
- Race is seeking funding from US partners or US grants to support paediatric (PRV) study
- Four planned Australian studies to be part-funded by R&D tax credits (43.5%)

RACE ONCOLOGY

L40 140 William St, Melbourne, VIC 3000

info@raceoncology.com

+61 3 9098 8750